Appendix 1Submissions and Additional Information
Submissions
1Department of Health and Aged Care
2National Health and Medical Research Council
Attachment
3Rare Cancers Australia
4Cancer Council Australia, the Cancer Nurses Society of Australia, the Clinical Oncology Society of Australia, Private Cancer Physicians of Australia, the Medical Oncology Group of Australia and the Lung Foundation Australia
5Royal Australian College of General Practitioners
6Children's Cancer Institute
7National Rural Health Alliance
8Medicines Australia
9Roche
10Australian Genomics
11WA Health
12Queensland Health
13Tasmanian Government
14Sydney Children's Hospitals Network
15Australian Nuclear Science and Technology Organisation
16Australian Diagnostic Imaging Association
17The Society of Hospital Pharmacists of Australia
18Ovarian Cancer Australia
19Head and Neck Cancer Australia
20PanKind, The Australian Pancreatic Cancer Foundation
21Pancare Foundation
Attachment
22Melanoma Patients Australia
23Minderoo Foundation
24VCCC Alliance
25TROG Cancer Research
26Australian Rare Cancer Portal
27Ovarian Cancer Research Foundation
28Victorian Cancer Biobank
29Peter MacCallum Cancer Centre
30Ipsen
31The Australian Bragg Centre for Proton Therapy and Research
32The Daffodil Centre and the University of Sydney Cancer Research Network
33Noxopharm
34Cancer Trials Australia
35Dr Jane Tiller and Associate Professor Paul Lacaze, Public Health Genomics Program, Monash University
36Dr Minmin Li FRACP and Associate Professor Kathy Tucker AO FRACP
37TrialHub
38NeuroEndocrine Cancer Australia
5 Attachments
39Leukaemia Foundation
40Movember Foundation
41AstraZeneca
42Bayer Australia
43Cancer Australia
44Omico
Attachment
45Dr S. Cox
45.1 Supplementary submission
46Bristol Myers Squibb Australia
47Telix Pharmaceuticals
48National Aboriginal Community Controlled Health Organisation
49IQVIA Australia
Attachment
50Professor John R Zalcberg AO
51UCB Australia
52Novartis
53MSD Australia
54Lana
55Jim
56Kim
57Michael
58Neuroblastoma Australia
59Grace
60Tanya
61Syd
62Michelle
63Emma
64Emily
65Leona
66Lynn
67Jon
68Ann
69Brittany
70Kathryn
71Michael
72Belinda
73Christopher
74Jean
75Jenny
76Angie
77Kerryn
78Jan
79Susan
80Milton
81Claudia
82Shae
83Kim
84Sandra
85Jaimee
86Mary
87Mary
88Peter
89Ailsa
90Alison
91Name Withheld
92Kristina and Brett
93Beau
94Name Withheld
95Christine
96Gay
97Dr Richard Stuckey
98Name Withheld
99Name Withheld
100Yvonne
101Glen
102Name Withheld
103Keanna and Fiore
104Name Withheld
105David
106Name Withheld
107Megan
108Jessica
109Danielle
110Ron
111Caitlin
112Sarah
113Sarah
114Cure Our Ovarian Cancer
115Jenaya
116Judi
117Ada
118Doreen
119WMozzies
120AbbVie
121Jamie
122Natalie
123Name Withheld
124Name Withheld
125Professor Matthew Dun
126Eleni
127Lorraine, Heath, Frith & Daniel, Dominic, Elannise
128Megan
129Kaye
130Dr Robert Thornton
131Peter
132Joyce
133Elnaz
134Andrea
135Anita
136Robin
137Alan
138Name Withheld
139Megan
140Associate Professor Gabrielle Cehic AM
141Le-Anne
142Russell
143Mr Ryan Paterson
144Royal College of Pathologists of Australasia
145Cancer Council Tasmania
146The Hospital Research Foundation Group
147Angel Flight
148Menzies Institute for Medical Research, University of Tasmania
149The Kinghorn Cancer Centre and St Vincent's Hospital Sydney
Additional Information
1Additional information provided by Cancer Australia, Australian Cancer Plan Summary Report; received 16 January 2024
2Additional information provided by Victoria Rare Cancer Trials Alliance, Addendum; received 9 February 2024
3Additional information provided by Neuroendocrine Clinical Nurse Consultant Kate Wakelin, Improving rates of diagnosis of neuroendocrine cancers; received 15 February 2024
4Additional information provided by Glen, Private Capacity, Additional comments to public hearing appearance; received 20 February 2024
5Additional information provided by Professor Peter Baade and Distinguished Professor Kerrie Mengersen, Latest trends in rare cancer diagnoses (counts), diagnoses rates and survival for all Australia; received 7 February 2024
Answer to Question on Notice
1Answers to questions taken on notice by Cancer Council Australia at a public hearing on 31 January 2024; received 9 February 2024.
2Answers to questions taken on notice by Private Cancer Physicians of Australia at a public hearing on 31 January 2024; received 7 February 2024.
3Answers to questions taken on notice by Sydney Children's Hospital Network at a public hearing on 31 January 2024; received 6 February 2024.
4Answers to questions taken on notice by Roche at a public hearing on 31 January 2024; received 5 February 2024.
5Answers to questions taken on notice by Australasian Leukaemia and Lymphoma Group at a public hearing on 1 February 2024; received 9 February 2024.
6Answers to questions taken on notice by NeuroEndocrine Cancer Australia at a public hearing on 1 February 2024; received 9 February 2024.
7Answers to questions taken on notice by Cancer Trials Australia at a public hearing on 1 February 2024; received 6 February 2024.
8Answers to questions taken on notice by Ipsen at a public hearing on 1 February 2024; received 13 February 2024.
9Answers to questions taken on notice by Ovarian Cancer Australia at a public hearing on 1 February 2024; received 9 February 2024.
10Answers to questions taken on notice by The Royal Australian College of General Practitioners at a public hearing on 1 February 2024; received 16 February 2024.
11Answers to questions taken on notice by The Daffodil Centre, Sydney Cancer Partners at a public hearing on 31 January 2024; received 19 February 2024.
12Answers to questions taken on notice by the Department of Health and Aged Care at a public hearing on 1 March 2024; received 27 March 2024
13Answers to questions taken on notice by Dr Melanie Wuttke and Dr Anna Johnston at a public hearing on 20 February 2024; received 26 April 2024
14Answers to questions taken on notice by Cancer Australia at a public hearing on 1 March 2024; received 13 March 2024.
15Answers to questions taken on notice by National Rural Health Alliance at a public hearing on 1 March 2024; received 15 March 2024.
16Answers to questions taken on notice by Australian Teletrial Program at a public hearing on 1 March 2024; received 15 March 2024.
17Answers to questions taken on notice by Rare Cancers Australia at a public hearing on 31 January 2024; received 15 February and 11 March 2024.
18Answers to questions taken on notice by Professor Jane Tiller at a public hearing on 1 February 2024; received 16 March 2024.
Tabled Documents
1Australian Cancer Atlas, Slide deck, tabled at public hearing on 31 January 2024
2Australian Cancer Atlas, Journal article regarding geographical and spatial disparities in the incidence and survival of rare cancers in Australia, tabled at public hearing on 31 January 2024
3Dr Richard Mitchell, Opening statement, tabled at public hearing on 31 January 2024
4IQVIA, Information regarding cancer treatment timelines and case studies, tabled at public hearing on 31 January 2024
5Professor Matthew Dun, Opening statement, tabled at public hearing on 31 January 2024
6Rotary Outreach Myeloma Project, Opening statement, tabled at public hearing on 1 February 2024
7Dr Jane Tiller and Associate Professor Paul Lacaze, Australian Genetics and Life Insurance Moratorium: Monitoring the Effectiveness and Response, Final Stakeholder Report, tabled at public hearing on 1 February 2024